Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
IPO Year: 2025
Exchange: NASDAQ
Website: vincerx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2022 | $25.00 | Buy | HC Wainwright & Co. |
| 12/23/2021 | $25.00 | Overweight | Cantor Fitzgerald |
| 11/1/2021 | $24.00 | Outperform | SVB Leerink |
| 9/13/2021 | $30.00 | Buy | Laidlaw |
| 8/25/2021 | $26.00 | Buy | B. Riley Securities |
| 8/13/2021 | $33.00 → $30.00 | Buy | Chardan Capital |
EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)
EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)
EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
S-8 POS - Vincerx Pharma, Inc. (0001796129) (Filer)
POS AM - Vincerx Pharma, Inc. (0001796129) (Filer)
POS AM - Vincerx Pharma, Inc. (0001796129) (Filer)
Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025 SAN MATEO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission ("SEC") on or about April 28, 2025, which will remove Vincerx's common stock from listing and registration on The Nasdaq Stock Market ("Nasdaq"). On April 14, 2025, Vincerx received written notice from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger. Following this decision, the Company's board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities. "I want to express our deepest gratitude to the investigators, patients, employees, and partners who have supported Vincerx's mission," said Raquel Izumi, Ph.D., Acting Chief Executive Officer of Vincerx. "Your co
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has entered into a non-binding letter of intent ("LOI") with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx. Under the proposed terms, a subsidiary of Vincerx would merge into QumulusAI, with QumulusAI stockholders receiving shares of Vincerx common stock.
SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated. As a result, the board of directors will reassess the Company's strategic alternatives, including out-licensing, merger and acquisition opportunities (including reverse mergers), the sale of assets and technologies, and winding down operations, among other potential transactions. As of February 26, 2025, the Company had approximately $3.9 million in cash. The Company's cash runway is expected to extend through late Q2 2025. Forward-L
SAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today highlighted Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, for patients with solid tumors. The companies also provided insights into their proposed strategic merger, which aims to advance OQY-3258 into global Phase 3 trials and build a differentiated ADC pipeline by leveraging their combined expertise.
SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which will be effective as of January 27, 2025 at 4:01 p.m., Eastern Time. Vincerx's common stock will continue trading on The Nasdaq Stock Market ("Nasdaq") under the existing symbol (VINC) and will begin trading on a split-adjusted basis when the market opens on January 28, 2025 with a new CUSIP number. The reverse stock split was approved by Vinc
PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction
PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the Company's novel CD123-targeted antibody-drug conjugate (ADC) developed with the Company's next-generation VersAptx™ platform. "We believe VIP943 is a highly differentiated and valuable asset, and we remain fully committed to advancing this program," said Ahmed Hamdy, M.D., Chief Executive Officer. "As we shared in October, the Phase
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1 dose-escalation studies of small molecule drug-conjugate (SMDC), VIP236, and CDK9 inhibitor, enitociclib, and identified the maximum tolerated dose Expected cash runway into early 2025 PALO ALTO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quart
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology Vincerx focusing resources on continued development of VIP943 Expected cash runway into early 2025 Management to host webcast and Q&A today at 5:00 PM EDT to review pipeline and corporate updates, followed by commentary from key opinion leader Dr. M. Yair Levy PALO ALTO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting thera
3 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00
Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00
SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00
Laidlaw initiated coverage of Vincerx with a rating of Buy and set a new price target of $30.00
B. Riley Securities initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $26.00
Chardan Capital reiterated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $30.00 from $33.00 previously
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)